peter kolchinsky age

Daphne Zohar is the founder and CEO of PureTech. Peter also leads the firms engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. In his role at Catamaran, he helped secure a Series A financing with a syndicate of leading investors, rapidly recruit an experienced cell therapy team, access enabling technologies, build a broad patent estate, and design external communication strategies. Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur and Head of the team executing a strategy for integrating influenza vaccine development with machine learning and antigen design. As the Chief Scientific Officer at Mustang Bio, Sadik managed the foundational build-out of the companys preclinical and manufacturing activities. Prior to joining RAVen, Kat was a Partner at van den Boom & Associates where she provided accounting and finance services including new company formation through IPO and public company accounting support, SOX compliance implementation, and financial modeling to several public and private life science companies. Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street. Before joining Proteon, Tim was the COO of Trine Pharmaceuticals and he held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. He holds a BS in Biology from the College of William and Mary, where he studied the impact of ecological fragmentation on the prevalence of ticks and their bacterial pathogens. As the first and founding member of Kymeras scientific team, Jesse was responsible for building the companys industry-leading targeted protein degradation platform and pipeline, and he helped secure the companys Series A and B financings as well as a partnership with Vertex. In these commercial roles, he initiated innovative discovery deal structures with venture companies, research foundations, and large integrated deals with pharmaceutical companies. Jacquelines primary responsibility is to partner with the Investment Team to develop quantitative analyses that inform investment decisions and improve core processes throughout the firm. He holds a BA from Cornell University and a PhD in Virology from Harvard University. James primary responsibilities are to advise RA Capital on public and private investments, coordinate with portfolio companies regarding deal structures and terms, and provide counsel and oversight on regulatory matters. Daniel has a BS in Mechanical Engineering from Lehigh University and a MS in Energy Policy & Climate from Johns Hopkins University. Michaels primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. James McArthur is an Advisor for RA Capital Management. In this role, Emily works closely with senior leaders, Venture Partners and Managing Directors within the Venture Team at RA Capital and within RAVen. Prior to KPMG, Ryan worked at Morris and Morris, P.C. Prior to RA, Henry gained experience as an Investment Banking Analyst at SVB Leerink. The Great American Drug Deal examines the healthcare landscape through the lens of this contract, including the government's role in inventing drugs, direct-to-consumer advertising, the opioid crisis, the price-jacking of old drugs, and the impact on America of lower drug costs in other countries. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, andWerewolf Therapeutics. Prior to RAVen, Scott was President and Managing Director of The Branta Group LLC, a healthcare company formation, capital investment, and strategic advisory firm known for taking an active management role with its clients and portfolio companies in the biotechnology, medical device, diagnostics, venture capital, and private equity sectors. Emilie has previously held similar roles at FLAG Capital Management and Bain Capital. Michael holds a BS in Exercise Science from Brigham Young University and an MD from the University of Texas Southwestern School of Medicine. Jaimie previously held roles in non-profit and medical settings and worked at Goldman Sachs where she was an Executive Assistant. Matt Beverly is a Senior Software Engineer at RA Capital Management. All rights reserved. Astha is a Senior Data Analyst Associate at RA Capital Management. He previously worked as a corporate attorney at Foley Hoag LLP and Cooley LLP. His graduate research investigated the role of fimbria in Bordetella adherence and virulence. Jesse also held research leadership roles at Moderna Therapeutics and Millennium Pharmaceuticals, where he was responsible for developing novel platforms and leading discovery programs. Craig Randall is Assistant General Counsel at RA Capital Management and Counsel at RA Ventures, RA Capital's incubator for new companies. He also provided additional system administration and training for the desktop engineering team. Prior to RA, Gunes served as a scientist within the PCMM Program at Boston Childrens Hospital and her research focused on biophysical characterization of different amyloid fibrils. Laura works on new company creation and early-stage investments, and serves as a Board Director for Be Biopharma, Expansion Therapeutics, Hemab, and Aliada Therapeutics. Peter has a BS in Biology with minors in both Chemistry and Spanish for the Medical Professions from the University of North Carolina at Chapel Hill. Joshs primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. Prior to this role, Tom conducted research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities as a Senior Research Assistant. Generali's No.3 investor Caltagirone withholds backing for 2022 accounts -sources, Musk says Tesla likely to launch full self-drive technology 'this year', Exclusive: JPMorgan employees gripe about Dimon's return-to-office edict, SpaceX rocket explosion illustrates Elon Musk's 'successful failure' formula, Cucinelli posts 33% rise in Q1 sales, confirms 2023 revenue growth forecast, Exclusive-Peter Thiel, Republican megadonor, won't fund candidates in 2024 - sources, Virginia Governor Youngkin 'humbled' by talk of possible presidential run, European Midday Briefing: Mood Brighter After -2-, Tim Cook unveils new Apple store in India, Morgan Stanley's dealmaking CEO Gorman signals more transactions to come, RA Capital Management LP (Private Equity). During his time at Flagship, Tom also served as Co-Founder, Head of Translational Biology at a stealth ProtoCo. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management.

Sugar: The Bitter Truth Transcript, Is Jonathan On Let's Make A Deal Married, Mountbatten Family Net Worth, Cyclones Baseball Tryouts, Articles P